- Home
- TALO vs MNKD Comparison
TALO vs MNKD Comparison
Compare TALO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALO
- MNKD
- Stock Information
- Founded
- TALO 2011
- MNKD 1991
- Country
- TALO United States
- MNKD United States
- Employees
- TALO N/A
- MNKD N/A
- Industry
- TALO Oil & Gas Production
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- TALO Energy
- MNKD Health Care
- Exchange
- TALO Nasdaq
- MNKD Nasdaq
- Market Cap
- TALO 1.2B
- MNKD 1.4B
- IPO Year
- TALO N/A
- MNKD 2004
- Fundamental
- Price
- TALO $8.11
- MNKD $4.56
- Analyst Decision
- TALO Buy
- MNKD Buy
- Analyst Count
- TALO 8
- MNKD 6
- Target Price
- TALO $14.38
- MNKD $8.92
- AVG Volume (30 Days)
- TALO 1.9M
- MNKD 1.5M
- Earning Date
- TALO 05-05-2025
- MNKD 05-08-2025
- Dividend Yield
- TALO N/A
- MNKD N/A
- EPS Growth
- TALO N/A
- MNKD 215.86
- EPS
- TALO 0.14
- MNKD 0.10
- Revenue
- TALO $2,055,748,000.00
- MNKD $297,595,000.00
- Revenue This Year
- TALO N/A
- MNKD $14.23
- Revenue Next Year
- TALO N/A
- MNKD $14.56
- P/E Ratio
- TALO $55.81
- MNKD $46.04
- Revenue Growth
- TALO 31.54
- MNKD 32.50
- 52 Week Low
- TALO $6.23
- MNKD $4.17
- 52 Week High
- TALO $13.57
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- TALO 57.23
- MNKD 38.80
- Support Level
- TALO $7.27
- MNKD $4.42
- Resistance Level
- TALO $8.60
- MNKD $5.05
- Average True Range (ATR)
- TALO 0.41
- MNKD 0.18
- MACD
- TALO 0.16
- MNKD 0.00
- Stochastic Oscillator
- TALO 73.10
- MNKD 20.59
About TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.